Why Niagen Bioscience’s next investor meetings could sharpen the NAD+ market debate

NAD+ is hot, but credibility is scarce. Niagen Bioscience now has to prove healthspan science can support durable investor trust.

NAD+ is hot, but credibility is scarce. Niagen Bioscience now has to prove healthspan science can support durable investor trust.

Discover why Standard Process’ Cultivate symposium aims to close clinical education gaps in whole-food nutrition and reshape healthy aging care for practitioners.